AR108591A1 - Composición acuosa que contiene atropina - Google Patents
Composición acuosa que contiene atropinaInfo
- Publication number
- AR108591A1 AR108591A1 ARP170101418A ARP170101418A AR108591A1 AR 108591 A1 AR108591 A1 AR 108591A1 AR P170101418 A ARP170101418 A AR P170101418A AR P170101418 A ARP170101418 A AR P170101418A AR 108591 A1 AR108591 A1 AR 108591A1
- Authority
- AR
- Argentina
- Prior art keywords
- buffer
- aqueous composition
- composition according
- atropina
- composition containing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 7
- 229930003347 Atropine Natural products 0.000 title abstract 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title 1
- 239000000872 buffer Substances 0.000 abstract 7
- 229960000686 benzalkonium chloride Drugs 0.000 abstract 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 abstract 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 abstract 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 abstract 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- 229960000396 atropine Drugs 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000007979 citrate buffer Substances 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000002357 osmotic agent Substances 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 abstract 1
- 229960000281 trometamol Drugs 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/08—Mydriatics or cycloplegics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Materials For Photolithography (AREA)
Abstract
Composición acuosa que comprende 0,001 - 0,1% (p/v) de atropina o una sal de ésta, un polímero soluble en agua y el amortiguador (I), cuyo pH está en el rango de 6 o menos, donde el amortiguador (I) es al menos uno seleccionado del grupo que consiste en un amortiguador de fosfato, un amortiguador de aminocarboxilato, un amortiguador de carbonato, un amortiguador de acetato, un amortiguador de tartrato, un amortiguador de borato y trometamol. Reivindicación 6: La composición acuosa de acuerdo con cualquiera de las reivindicaciones 1 a 5, caracterizada porque también comprende un amortiguador de citrato como amortiguador (II). Reivindicación 11: La composición acuosa de acuerdo con cualquiera de las reivindicaciones 8 a 10, caracterizada porque el derivado de celulosa es hidroxietil celulosa. Reivindicación 14: La composición acuosa de acuerdo con cualquiera de las reivindicaciones 1 a 13, caracterizada porque comprende menos de 50 ppm de cloruro de benzalconio. Reivindicación 15: La composición acuosa de acuerdo con cualquiera de las reivindicaciones 1 a 14, caracterizada porque sustancialmente no comprende cloruro de benzalconio. Reivindicación 19: La composición acuosa de acuerdo con cualquiera de las reivindicaciones 16 a 18, caracterizada porque el agente osmótico no iónico es glicerina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG10201604200P | 2016-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108591A1 true AR108591A1 (es) | 2018-09-05 |
Family
ID=60411416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101418A AR108591A1 (es) | 2016-05-25 | 2017-05-24 | Composición acuosa que contiene atropina |
Country Status (15)
Country | Link |
---|---|
US (1) | US20210267885A1 (es) |
EP (2) | EP3463360B1 (es) |
JP (4) | JP6590860B2 (es) |
KR (3) | KR20230141882A (es) |
CN (3) | CN117205209A (es) |
AR (1) | AR108591A1 (es) |
CA (1) | CA3023149A1 (es) |
EA (1) | EA201892703A1 (es) |
ES (1) | ES2929368T3 (es) |
MY (1) | MY189774A (es) |
PH (1) | PH12018502421A1 (es) |
SG (1) | SG11201809822SA (es) |
TW (3) | TWI791438B (es) |
UA (1) | UA126195C2 (es) |
WO (1) | WO2017204262A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
JP2020509085A (ja) | 2017-02-21 | 2020-03-26 | シンガポール ヘルス サービシーズ プライベート リミテッド | アトロピンを含む、近視の発症を予防するまたは遅らせるための組成物および方法 |
KR102281667B1 (ko) | 2017-05-11 | 2021-07-23 | 네바카 아이엔씨. | 아트로핀 약학 조성물 (atropine pharmaceutical compositions) |
CN114533652A (zh) * | 2018-09-25 | 2022-05-27 | 沈阳兴齐眼科医院有限公司 | 药物组合物、其制备方法和用途 |
EP3701938B8 (en) | 2019-03-01 | 2024-02-21 | Medivis S.R.L. | Ophthalmic formulations based on atropine |
BR112023001720A2 (pt) | 2020-08-04 | 2023-03-28 | Santen Pharmaceutical Co Ltd | Composição farmacêutica para o tratamento da miopia, prevenção da miopia e/ou supressão da progressão da miopia, para suprimir o alongamento do comprimento axial e para suprimir o erro de refração, e, uso de (+)-11-[2-[2-[(dietilamino)metil]-1-piperidinil]acetil]-5,11-di-hidro-6h-pirido[2,3-b][1,4]benzodiazepina-6-ona ou um sal da mesma |
EP4230210A1 (en) * | 2020-10-14 | 2023-08-23 | Santen Pharmaceutical Co., Ltd. | Stable pharmaceutical composition |
EP4237421A1 (en) | 2020-11-02 | 2023-09-06 | Trethera Corporation | Crystalline forms of a deoxycytidine kinase inhibitor and uses thereof |
WO2022130337A1 (en) * | 2020-12-17 | 2022-06-23 | Sun Pharmaceutical Industries Limited | An aqueous sterile solution of atropine for ophthalmic use |
EP4088714A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
EP4088713A1 (en) | 2021-05-10 | 2022-11-16 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Ophthalmic pharmaceutical composition comprising atropine |
US20230120997A1 (en) * | 2021-10-18 | 2023-04-20 | Ocular Science, Inc. | Compositions and methods for myopia control and orthokeratology lenses treatment |
CN114129511A (zh) * | 2021-12-07 | 2022-03-04 | 河南润弘制药股份有限公司 | 一种具有改进稳定性的硫酸阿托品注射液 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2617508B2 (ja) * | 1988-02-05 | 1997-06-04 | エーザイ株式会社 | 安定なジフェンヒドラミン含有水溶液 |
US20030096831A1 (en) | 2000-01-18 | 2003-05-22 | Stone Richard A. | Ocular growth and nicotinic antagonists |
HUP0304071A2 (hu) * | 2001-05-25 | 2004-04-28 | Valley Forge Pharmaceuticals | Pirenzepine-tartalmú szemészeti gélkészítmény és eljárás az előállítására |
US20070254914A1 (en) * | 2006-05-01 | 2007-11-01 | Non-Profit Organization Chang Gung Memorial Hospital | Low-concentration atropine solution for preventing myopia progression and preparing method thereof |
JP2007308398A (ja) * | 2006-05-17 | 2007-11-29 | Chang Gung Memorial Hospital | 目薬、及びその製造方法 |
CA2688811A1 (en) * | 2007-05-21 | 2008-11-27 | Neuroptix Corporation | Ophthalmic formulations of amyloid-beta contrast agents and methods of use thereof |
WO2012161655A1 (en) | 2011-05-23 | 2012-11-29 | Singapore Health Services Pte Ltd | Composition and/or method for reducing and/or preventing myopia progression comprising atropine |
US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
US20160009705A1 (en) * | 2014-06-24 | 2016-01-14 | Sydnexis, Inc. | Ophthalmic composition |
JP2017102939A (ja) * | 2016-12-26 | 2017-06-08 | 株式会社プロフィールド | オーサリング装置、オーサリング方法、およびプログラム |
KR102281667B1 (ko) * | 2017-05-11 | 2021-07-23 | 네바카 아이엔씨. | 아트로핀 약학 조성물 (atropine pharmaceutical compositions) |
-
2017
- 2017-05-24 CN CN202311238651.XA patent/CN117205209A/zh active Pending
- 2017-05-24 TW TW106117194A patent/TWI791438B/zh active
- 2017-05-24 KR KR1020237031744A patent/KR20230141882A/ko not_active Application Discontinuation
- 2017-05-24 TW TW110141612A patent/TW202206070A/zh unknown
- 2017-05-24 CA CA3023149A patent/CA3023149A1/en active Pending
- 2017-05-24 EA EA201892703A patent/EA201892703A1/ru unknown
- 2017-05-24 TW TW112102321A patent/TW202325296A/zh unknown
- 2017-05-24 UA UAA201812662A patent/UA126195C2/uk unknown
- 2017-05-24 WO PCT/JP2017/019423 patent/WO2017204262A1/en unknown
- 2017-05-24 AR ARP170101418A patent/AR108591A1/es unknown
- 2017-05-24 CN CN202311240197.1A patent/CN117205210A/zh active Pending
- 2017-05-24 CN CN201780031738.6A patent/CN109310687B/zh active Active
- 2017-05-24 EP EP17802848.6A patent/EP3463360B1/en active Active
- 2017-05-24 KR KR1020227039104A patent/KR102580933B1/ko active IP Right Grant
- 2017-05-24 KR KR1020187037233A patent/KR20190013877A/ko active Application Filing
- 2017-05-24 MY MYPI2018001914A patent/MY189774A/en unknown
- 2017-05-24 US US16/303,686 patent/US20210267885A1/en active Pending
- 2017-05-24 SG SG11201809822SA patent/SG11201809822SA/en unknown
- 2017-05-24 JP JP2017102939A patent/JP6590860B2/ja active Active
- 2017-05-24 ES ES17802848T patent/ES2929368T3/es active Active
- 2017-05-24 EP EP22189717.6A patent/EP4112055A1/en active Pending
-
2018
- 2018-11-16 PH PH12018502421A patent/PH12018502421A1/en unknown
-
2019
- 2019-09-17 JP JP2019168569A patent/JP6886502B2/ja active Active
-
2021
- 2021-05-14 JP JP2021082578A patent/JP7224390B2/ja active Active
-
2023
- 2023-02-07 JP JP2023016850A patent/JP2023058574A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2017204262A1 (en) | 2017-11-30 |
UA126195C2 (uk) | 2022-08-31 |
EP3463360B1 (en) | 2022-08-31 |
KR20190013877A (ko) | 2019-02-11 |
MY189774A (en) | 2022-03-04 |
EP3463360A4 (en) | 2020-01-29 |
TW202325296A (zh) | 2023-07-01 |
KR20220154842A (ko) | 2022-11-22 |
JP2020007356A (ja) | 2020-01-16 |
JP7224390B2 (ja) | 2023-02-17 |
EA201892703A1 (ru) | 2019-04-30 |
CA3023149A1 (en) | 2017-11-30 |
PH12018502421A1 (en) | 2019-09-30 |
TW201808289A (zh) | 2018-03-16 |
KR102580933B1 (ko) | 2023-09-19 |
CN109310687A (zh) | 2019-02-05 |
EP3463360A1 (en) | 2019-04-10 |
JP6886502B2 (ja) | 2021-06-16 |
CN117205210A (zh) | 2023-12-12 |
JP6590860B2 (ja) | 2019-10-16 |
JP2021120404A (ja) | 2021-08-19 |
CN117205209A (zh) | 2023-12-12 |
TW202206070A (zh) | 2022-02-16 |
TWI791438B (zh) | 2023-02-11 |
KR20230141882A (ko) | 2023-10-10 |
JP2018021007A (ja) | 2018-02-08 |
SG11201809822SA (en) | 2018-12-28 |
JP2023058574A (ja) | 2023-04-25 |
EP4112055A1 (en) | 2023-01-04 |
US20210267885A1 (en) | 2021-09-02 |
CN109310687B (zh) | 2023-10-20 |
ES2929368T3 (es) | 2022-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108591A1 (es) | Composición acuosa que contiene atropina | |
CL2018001474A1 (es) | Mezcla seca que comprende sal de alginato; goma vegetal hidrocoloide de galactamanano; y almidon para la fabricacion de una composicion de alginato para envoltura de productos alimenticios que ademas comprende: poliol; humo liquido; y un agente amortiguador tal como glucono-delta-lactona, ácido acético, y carbonato de sodio (divisional de 408-2017). | |
BR112022004514A2 (pt) | Produto oral com uma amina básica e um agente de pareamento iônico | |
JP2018021007A5 (es) | ||
AR074541A1 (es) | Composiciones desinfectantes de plata naturales | |
CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
AR101690A1 (es) | Composiciones tensioactivas acuosas | |
BR112018074352A2 (pt) | partículas de nanoalume contendo um agente de dimensionamento | |
AR081520A1 (es) | Composicion farmaceutica que comprende una dispersion solida de tacrolimus en un vehiculo | |
BR112018000701A2 (pt) | composição de limpeza não corrosiva, altamente alcalina | |
MX2017014464A (es) | Composicion reticulante que incluye silicato sintetico en capas. | |
EA201690079A1 (ru) | Композиция, содержащая глутаминовую-n,n-диуксусную кислоту (glda), воду и фермент | |
PH12016500909B1 (en) | Solutons for increasing the stability and shelf life of an organ tissue preservation solution | |
AR105044A1 (es) | Soluciones de esteroides neuroactivos y sus métodos de uso, recipiente | |
CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
HRP20220793T1 (hr) | Oftalmološki vodeni sastav | |
AR092691A1 (es) | Composicion farmaceutica que comprende rebamipida | |
RU2017102325A (ru) | Препарат рокурония с улучшенной стабильностью | |
BR112017007582A2 (pt) | recipiente, uso de um recipiente, e, processo para fabricar um recipiente ou um compartimento de um recipiente. | |
BR112013033060A2 (pt) | solução oftálmica contendo ácido hialurônico ou sal deste e propileno glicol | |
AR087371A1 (es) | Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos | |
BR112018011564A2 (pt) | solução de dióxido de titânio neutra, fotoativa concentrada | |
AR089831A1 (es) | Una composicion y un metodo para tratar sustratos | |
MX2015005837A (es) | Composicion de enema para el tratamiento de colitis ulcerosa que tiene estabilidad a largo plazo. | |
AR098999A1 (es) | Proceso de disolución o extracción de al menos un metal precioso de un material fuente que lo contiene y composición utilizada |